Evidence map›Paper›PMID 25832697›Full record

ArticleInternational journal of radiation oncology, biology, physics2015

High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer.

Adam R Wolfe, Rachel L Atkinson, Jay P Reddy, Bisrat G Debeb, Richard Larson, Li Li, Hiroko Masuda, Takae Brewer, Bradley J Atkinson, Abeena Brewster and 2 more

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Examining the expression of low-density lipoprotein receptor (Molecular biology research communications · 2024
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Adam R WolfeDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas.
Rachel L AtkinsonMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas.
Jay P ReddyDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Bisrat G DebebDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Richard LarsonDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Li LiDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Hiroko MasudaDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Takae BrewerDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Bradley J AtkinsonDepartment of Clinical Pharmacy Services, University of Texas MD Anderson Cancer Center, Houston, Texas.
Abeena BrewsterMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas.
Naoto T UenoDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.
Wendy A WoodwardDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: wwoodward@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Human Breast Cancer Stem Cell SurrogatesR01CA138239 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CRISTOFANILLI, MASSIMO, REUBEN, JAMES MARTIN · 2008 to 2012
$2.8M
(PQD4) SIGNS OF INFLAMMATORY BREAST CANCER ARE CAUSED BY STROMAL FIELD EFFECTSR01CA180061 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WOODWARD, WENDY A · 2013 to 2016
$1.9M
Center for Clinical and Translational Sciences (CCTS)TL1TR000369 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$1.9M
NCATS NIH HHS TL1 TR000369NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA138239NCI NIH HHS R01 CA180061
6 · The paper itself

Abstract

purposeWe previously demonstrated that cholesterol-lowering agents regulate radiation sensitivity of inflammatory breast cancer (IBC) cell lines in vitro and are associated with less radiation resistance among IBC patients who undergo postmastectomy radiation. We hypothesized that decreasing IBC cellular cholesterol induced by treatment with lipoproteins would increase radiation sensitivity. Here, we examined the impact of specific transporters of cholesterol (ie lipoproteins) on the responses of IBC cells to self-renewal and to radiation in vitro and on clinical outcomes in IBC patients. METHODS AND MATERIALS: Two patient-derived IBC cell lines, SUM 149 and KPL4, were incubated with low-density lipoproteins (LDL), very-low-density lipoproteins (VLDL), or high-density lipoproteins (HDL) for 24 hours prior to irradiation (0-6 Gy) and mammosphere formation assay. Cholesterol panels were examined in a cohort of patients with primary IBC diagnosed between 1995 and 2011 at MD Anderson Cancer Center. Lipoprotein levels were then correlated to patient outcome, using the log rank statistical model, and examined in multivariate analysis using Cox regression.

resultsVLDL increased and HDL decreased mammosphere formation compared to untreated SUM 149 and KPL4 cells. Survival curves showed enhancement of survival in both of the IBC cell lines when pretreated with VLDL and, conversely, radiation sensitization in all cell lines when pretreated with HDL. In IBC patients, higher VLDL values (>30 mg/dL) predicted a lower 5-year overall survival rate than normal values (hazard ratio [HR] = 1.9 [95% confidence interval [CI]: 1.05-3.45], P=.035). Lower-than-normal patient HDL values (<60 mg/dL) predicted a lower 5-year overall survival rate than values higher than 60 mg/dL (HR = 3.21 [95% CI: 1.25-8.27], P=.015).

conclusionsThis study discovered a relationship among the plasma levels of lipoproteins, overall patient response, and radiation resistance in IBC patients and IBC patient-derived cell lines. A more expansive study is needed to verify these observations.

Indexed as

Radiation ToleranceAnticholesteremic AgentsCell Line, TumorCell SurvivalCholesterolDNA RepairDyslipidemiasErbB ReceptorsFemaleForkhead Box Protein O3Forkhead Transcription FactorsHumansInflammatory Breast NeoplasmsIntercellular Signaling Peptides and ProteinsLipoproteins, HDLLipoproteins, VLDLAnticholesteremic AgentsCholesterolEGFR protein, humanErbB ReceptorsForkhead Box Protein O3Forkhead Transcription FactorsFOXO3 protein, humanIntercellular Signaling Peptides and ProteinsLipoproteins, HDLLipoproteins, VLDLProto-Oncogene Proteins c-aktvery high density lipoproteins

Identifiers

PMID25832697
PMCPMC4801170
OpenAlexW2120875487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.